8-K filing — Tempest Therapeutics, Inc. (TPST)
Filed: 2026-11-13 AccNo: 0001213900-26-119916 Size: 339 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Tempest Therapeutics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its pipeline, capital position, and board composition.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0001213900-26-119916 Size: 339 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Hebei Senlang Biotechnology's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates for global development outside of China.
Tempest Therapeutics, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 11, 2026.
Tempest Therapeutics has appointed Stephanie Horn-Warnock as Chief Financial Officer, Treasurer, and Corporate Secretary following the resignation of Constance Ames.